SCHEMBL19008908

SCHEMBL19008908

CC1(C)c2ccccc2-c2cnc(-c3ccc(-c4cc(-c5ccccc5)cc(-c5ccccc5)n4)c4ccccc34)nc21

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP19A1 P11511 1/20 0.35
▸ PDK2 Q15119 4/20 0.34
▸ SMN1; SMN2 Q16637 4/20 0.32
▸ MEN1 O00255 2/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ CYP1A2 P05177 2/20 0.32
▸ MAPT P10636 2/20 0.32
▸ CYP2C9 P11712 2/20 0.32
▸ CYP2C19 P33261 2/20 0.32
▸ LMNA P02545 2/20 0.32
▸ MAPK10 P53779 1/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32
▸ LTB4R Q15722 4/20 0.31
▸ ADORA3 P0DMS8 1/20 0.31
▸ ADORA2B P29275 1/20 0.31
▸ ADORA1 P30542 1/20 0.31
▸ NPC1 O15118 1/20 0.31
▸ PDGFRB P09619 1/20 0.31
▸ KDR P35968 1/20 0.31
▸ FLT3 P36888 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19008902 0.94 PDK2 (0.36) CYP19A1PDK2MEN1KMT2ALTB4R
SCHEMBL19008878 0.91 MEN1 (0.38) SMN1; SMN2MEN1KMT2ACYP1A2MAPT
SCHEMBL19008889 0.89 CYP19A1 (0.36) CYP19A1PDK2SMN1; SMN2MEN1KMT2A
SCHEMBL19008923 0.88 CYP19A1 (0.34) CYP19A1PDK2SMN1; SMN2MEN1KMT2A
SCHEMBL19008897 0.87 MEN1 (0.38) SMN1; SMN2MEN1KMT2ACYP1A2MAPT
SCHEMBL19008922 0.86 CYP19A1 (0.36) CYP19A1PDK2SMN1; SMN2MEN1KMT2A
SCHEMBL19008901 0.86 CYP19A1 (0.34) CYP19A1PDK2SMN1; SMN2CYP1A2MAPT
SCHEMBL19008900 0.84 PDK2 (0.36) CYP19A1PDK2SMN1; SMN2MEN1KMT2A
SCHEMBL19008873 0.83 TSHR (0.37) SMN1; SMN2MEN1KMT2ACYP1A2MAPT
SCHEMBL19008905 0.83 CYP19A1 (0.36) CYP19A1PDK2SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10461262-B2 Condensed cyclic compound and an organic light-emitting device including the same SAMSUNG DISPLAY CO., LTD. (KR) 2019-10-29 — — US disclosed
US-20170179408-A1 CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2017-06-22 — — US disclosed
US-20170179408-A1 CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2017-06-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10461262-B2 Condensed cyclic compound and an organic light-emitting device including the same CRY1, CRY2, CCNA1 CYP19A1 61/4885PDK2 1588/4885SMN1; SMN2 4406/4885
US-20170179408-A1 CONDENSED CYCLIC COMPOUND AND AN ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME CRY1, CRY2, CCNA1 CYP19A1 61/4885PDK2 1588/4885SMN1; SMN2 4406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback